Clinical Trials Logo
  1. Home
  2. HER2-positive Breast Cancer
  3. NCT04539938

A Study of Tucatinib Plus Trastuzumab Deruxtecan in HER2+ Breast Cancer — HER2CLIMB-04  

HER2 Positive Breast Cancer Clinical Trial

Official title:
A Single Arm, Open Label Phase 2 Study of Tucatinib in Combination With Trastuzumab Deruxtecan in Subjects With Previously Treated Unresectable Locally-Advanced or Metastatic HER2+ Breast Cancer

Clinical Trial Summary

This trial studies how well the drug tucatinib works when given with trastuzumab deruxtecan (T-DXd). It will also look at what side effects happen when these drugs are given together. A side effect is anything a drug does besides treating cancer. Participants in this trial have HER2-positive (HER2+) breast cancer that has either spread to other parts of the body (metastatic) or cannot be removed completely with surgery (unresectable). All participants will get both tucatinib and T-DXd.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT04539938
Study type Interventional
Source Seagen Inc.
Contact
Status Active, not recruiting
Phase Phase 2
Start date December 1, 2020
Completion date October 31, 2025
View Details
See also
  Status Clinical Trial Phase
Completed NCT01904903 - Cardiac Safety Study in Patients With HER2 + Breast Cancer Phase 2
Completed NCT02476539 - Study Evaluating Hemay022 In Subjects With HER2-Positive Advanced Breast Cancer Phase 1
Completed NCT01840306 - Exosomal and Free Extracellular RNAs and Proteins as Predictive Biomarkers for HER2 Therapies in Breast Cancer
Completed NCT03735966 - Neoadjuvant Study of Pyrotinib and Trastuzumab Plus Docetaxel and Carboplatin in HER2 Positive Breast Cancer Patients. Phase 2
Recruiting NCT01785420 - Pre Operative Trastuzumab in Operable Breast Cancer Phase 3
Recruiting NCT05132582 - A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer Phase 3
Terminated NCT00817362 - Efficacy and Safety of IPI-504 With Trastuzumab Pretreated, Locally Advanced or Metastatic HER2 Positive Breast Cancer Phase 2
Not yet recruiting NCT03947242 - Neoadjuvant Study of Pyrotinib and Trastuzumab Plus Vinorelbine in Trastuzumab-refractory HER2-Positive Breast Cancer. N/A
Terminated NCT02213744 - MM-302 Plus Trastuzumab vs. Chemotherapy of Physician's Choice Plus Trastuzumab in HER2-Positive Locally Advanced/Metastatic Breast Cancer Patients Phase 2/Phase 3
Completed NCT02362958 - A Multi-Center Study of Lapatinib in Patients With Trastuzumab-refractory Metastatic Breast Cancer Phase 2
Completed NCT02614794 - A Study of Tucatinib vs. Placebo in Combination With Capecitabine & Trastuzumab in Patients With Advanced HER2+ Breast Cancer Phase 2
Completed NCT03013504 - A Phase III Trial to Compare the Efficacy, Safety and Pharmacokinetics of HD201 to Herceptin® in HER2+ Early Breast Cancer Patients Phase 3
Completed NCT02682693 - Denosumab as an add-on Neoadjuvant Treatment (GeparX) Phase 2
Completed NCT02125344 - A Phase III Trial Comparing Two Dose-dense, Dose-intensified Approaches (ETC and PM(Cb)) for Neoadjuvant Treatment of Patients With High-risk Early Breast Cancer (GeparOcto) Phase 3
Recruiting NCT05252988 - Three Antidiarrheal Strategies in HER2+/HR+ Early Breast Cancer Patients Treated With Extended Adjuvant Neratinib Phase 2
Terminated NCT02963363 - Adapted Physical Activity for Breast Cancer HER2 Positive Patient N/A
Completed NCT02705859 - Phase Ib/II Trial of coPANlisib in Combination With Trastuzumab in HER2-positive Breast Cancer. (Panther Study) Phase 1
Active, not recruiting NCT02993198 - A Prospective Study of Breast Cancer Patients With Abnormal Strain Imaging Phase 2